146 related articles for article (PubMed ID: 34126129)
1. Time-in-range for monitoring glucose control: Is it time for a change?
Bellido V; Pinés-Corrales PJ; Villar-Taibo R; Ampudia-Blasco FJ
Diabetes Res Clin Pract; 2021 Jul; 177():108917. PubMed ID: 34126129
[TBL] [Abstract][Full Text] [Related]
2. Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
Krajnc M; Kravos Tramšek NA
Eur J Med Res; 2023 Mar; 28(1):111. PubMed ID: 36882852
[TBL] [Abstract][Full Text] [Related]
3. THE ADDED AND INTERPRETATIVE VALUE OF CGM-DERIVED PARAMETERS IN TYPE 1 DIABETES DEPENDS ON THE LEVEL OF GLYCEMIC CONTROL.
Helleputte S; De Backer T; Calders P; Pauwels B; Shadid S; Lapauw B
Endocr Pract; 2021 Jan; 27(1):44-50. PubMed ID: 33475500
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Glycemia Risk Index with Time in Range for Assessing Glycemic Quality.
Kim JY; Yoo JH; Kim JH
Diabetes Technol Ther; 2023 Dec; 25(12):883-892. PubMed ID: 37668665
[No Abstract] [Full Text] [Related]
5. Positioning time in range in diabetes management.
Advani A
Diabetologia; 2020 Feb; 63(2):242-252. PubMed ID: 31701199
[TBL] [Abstract][Full Text] [Related]
6. Relationship between key continuous glucose monitoring-derived metrics and specific cognitive domains in patients with type 2 diabetes mellitus.
Dong S; Wang L; Zhao C; Zhang R; Gao Z; Jiang L; Guo Y; Zhou H; Xu S
BMC Neurol; 2023 May; 23(1):200. PubMed ID: 37210479
[TBL] [Abstract][Full Text] [Related]
7. Hypoglycemia and glycemic variability of people with type 1 diabetes with lower and higher physical activity loads in free-living conditions using continuous subcutaneous insulin infusion with predictive low-glucose suspend system.
Montt-Blanchard D; Sánchez R; Dubois-Camacho K; Leppe J; Onetto MT
BMJ Open Diabetes Res Care; 2023 Mar; 11(2):. PubMed ID: 36944432
[TBL] [Abstract][Full Text] [Related]
8. Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials.
Maiorino MI; Signoriello S; Maio A; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Giugliano D; Esposito K
Diabetes Care; 2020 May; 43(5):1146-1156. PubMed ID: 32312858
[TBL] [Abstract][Full Text] [Related]
9. Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes.
Yoo JH; Choi MS; Ahn J; Park SW; Kim Y; Hur KY; Jin SM; Kim G; Kim JH
Diabetes Technol Ther; 2020 Oct; 22(10):768-776. PubMed ID: 32167394
[No Abstract] [Full Text] [Related]
10. Expert Recommendations for Using Time-in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient-Centered Glycemic Control in People With Diabetes.
Bellido V; Aguilera E; Cardona-Hernandez R; Diaz-Soto G; González Pérez de Villar N; Picón-César MJ; Ampudia-Blasco FJ
J Diabetes Sci Technol; 2023 Sep; 17(5):1326-1336. PubMed ID: 35470692
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of flash glucose monitoring in pregnant women with poorly controlled pregestational diabetes (FlashMom): A randomized pilot study.
Tumminia A; Milluzzo A; Festa C; Fresa R; Pintaudi B; Scavini M; Vitacolonna E; Napoli A; Sciacca L
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1851-1859. PubMed ID: 33975741
[TBL] [Abstract][Full Text] [Related]
12. Association between scanning frequency of flash glucose monitoring and continuous glucose monitoring-derived glycemic makers in children and adolescents with type 1 diabetes.
Suzuki J; Urakami T; Yoshida K; Kuwabara R; Mine Y; Aoki M; Morioka I
Pediatr Int; 2021 Feb; 63(2):154-159. PubMed ID: 32744360
[TBL] [Abstract][Full Text] [Related]
13. Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control.
Yoo JH; Kim JH
Diabetes Metab J; 2020 Dec; 44(6):828-839. PubMed ID: 33389957
[TBL] [Abstract][Full Text] [Related]
14. Benefits of a Switch from Intermittently Scanned Continuous Glucose Monitoring (isCGM) to Real-Time (rt) CGM in Diabetes Type 1 Suboptimal Controlled Patients in Real-Life: A One-Year Prospective Study
Préau Y; Galie S; Schaepelynck P; Armand M; Raccah D
Sensors (Basel); 2021 Sep; 21(18):. PubMed ID: 34577338
[TBL] [Abstract][Full Text] [Related]
15. Glycemic Metrics Derived From Intermittently Scanned Continuous Glucose Monitoring.
Hansen KW; Bibby BM
J Diabetes Sci Technol; 2022 Jan; 16(1):113-119. PubMed ID: 33269634
[TBL] [Abstract][Full Text] [Related]
16. The Optimal "Time in Range" and "Time below Range" are Difficult to Coordinate in Patients with Type 1 Diabetes.
Sekiguchi S; Yamada E; Nakajima Y; Matsumoto S; Yoshino S; Horiguchi K; Ishida E; Uehara R; Okada S; Yamada M
Tohoku J Exp Med; 2021 Nov; 255(3):221-227. PubMed ID: 34759118
[TBL] [Abstract][Full Text] [Related]
17. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.
Rodbard D
Diabetes Technol Ther; 2017 Jun; 19(S3):S25-S37. PubMed ID: 28585879
[TBL] [Abstract][Full Text] [Related]
18. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
[TBL] [Abstract][Full Text] [Related]
19. Significance of "Time below Range" as a Glycemic Marker Derived from Continuous Glucose Monitoring in Japanese Children and Adolescents with Type 1 Diabetes.
Urakami T; Yoshida K; Kuwabara R; Mine Y; Aoki M; Suzuki J; Morioka I
Horm Res Paediatr; 2020; 93(4):251-257. PubMed ID: 32950993
[TBL] [Abstract][Full Text] [Related]
20. Essential Continuous Glucose Monitoring Metrics: The Principal Dimensions of Glycemic Control in Diabetes.
Montaser E; Fabris C; Kovatchev B
Diabetes Technol Ther; 2022 Nov; 24(11):797-804. PubMed ID: 35714355
[No Abstract] [Full Text] [Related]
[Next] [New Search]
